论文部分内容阅读
观察乳杆菌活菌胶囊制剂治疗细菌性阴道病（ＢａｃｔｅｒｉａｌＶａｇｉｎｏｓｉｓ，简称ＢＶ）的疗效及安全性。方法：选择符合入选条件的病人，采用随机对照实验，乳杆菌活菌胶囊制剂组４１例，灭滴灵对照４１例。采用开放实验，乳杆菌活菌胶囊制剂治疗２１例。观察、记录病人在用药前、用药后第６天及停药后３天的临床表现、阴道分泌物ｐＨ值测定，胺实验及涂片检查线索细胞等；用以评价乳杆菌活菌胶囊制剂对细菌性阴道病的疗效。结果：乳杆菌活菌胶囊制剂和灭滴灵治疗细菌性阴道病，二者总有效率在症状方面，实验组为８０７７％，对照组为７９３１；在体征方面，实验组为７２９％，对照组为７６９％。统计学分析结果，相对应组间总有效率无显著差异（Ｐ＞００５）。结论：乳杆菌活菌胶囊制剂是治疗ＢＶ的安全有效药物，对肝肾功能无不良影响，亦无明显不良反应。
To observe the efficacy and safety of Lactobacillus live capsule in the treatment of Bacterial Vaginosis (BV). Methods: The patients who met the inclusion criteria were selected and randomized controlled trials were conducted. 41 cases were treated with Lactobacillus capsules and 41 cases were treated with metronidazole. Using open experiment, Lactobacillus live bacteria capsule preparation in 21 cases. Observe and record the patients before treatment, 6 days after treatment and 3 days after stopping the clinical manifestations, vaginal secretions pH value, amine test and smear check clue cells; to evaluate the Lactobacillus live capsule preparation Bacterial vaginosis curative effect. Results: Lactobacillus live capsule and metronidazole treatment of bacterial vaginosis, the total effective rate in the symptoms, the experimental group was 80 77%, the control group was 79 31; in signs, the experimental group was 72 9%, control group was 76 9%. Statistical analysis, the corresponding total effective rate between groups no significant difference (P> 0 05). Conclusion: Lactobacillus live bacteria capsule preparation is safe and effective treatment of BV drugs, no adverse effects on liver and kidney function, no obvious adverse reactions.